Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies
Journal of Alzheimer’s Disease | August 3, 2021
Pilotto A, Imarisio A, Carrarini C, Russo M, Masciocchi S, Gipponi S, Cottini E, Aarsland D, Zetterberg H, Ashton NJ, Hye A, Bonanni L and Padovani A
Journal of Alzheimer’s disease : JAD. 2021;82:913-919
This study was performed using the Quanterix HD-1 Analyzer.
Plasma neurofilament light chain (NfL) is a marker of neuronal damage in different neurological disorders and might predict disease progression in dementia with Lewy bodies (DLB). The study enrolled 45 controls and 44 DLB patients (including 17 prodromal cases) who underwent an extensive assessment at baseline and at 2 years follow-up. At baseline, plasma NfL levels were higher in both probable DLB and prodromal cases compared to controls. Plasma NfL emerged as the best predictor of cognitive decline compared to age, sex, and baseline severity variables. The study supports the role of plasma NfL as a useful prognostic biomarker from the early stages of DLB.
Share this page